Quick Answer
Apogee Therapeutics, Inc. reported Cash and Equivalents of $131.55 million for fiscal year 2025.
Apogee Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $131.55M | -7.2% |
| 2024 | $141.79M | +19.8% |
| 2023 | $118.32M | -22.1% |
| 2022 | $151.89M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $107.91M | -9.1% | -13.1% |
| June 30, 2025 | $124.19M | -59.6% | +16.2% |
| March 31, 2025 | $106.92M | -78.0% | -10.0% |
| September 30, 2024 | $118.78M | -36.9% | -61.3% |
| June 30, 2024 | $307.30M | +145.7% | -36.7% |
| March 31, 2024 | $485.46M | +243.5% | +157.9% |
| September 30, 2023 | $188.27M | — | +50.5% |
| June 30, 2023 | $125.07M | — | -11.5% |
- Apogee Therapeutics, Inc. showed a decrease of -7.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, Apogee Therapeutics, Inc.’s cash and equivalents has declined by 13.4% (from $151.89 million to $131.55 million).
- The most recent figure is from Apogee Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: